PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Affiliation auteurs!!!! Error affiliation !!!!
TitrePROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Type de publicationJournal Article
Year of Publication2019
AuteursHussain M., Mateo J., Fizazi K., Saad F., Shore N.D, Sandhu S., Chi K.N, Sartor O., Agarwal N., Olmos D., Thiery-Vuillemin A., Twardowski P., Mehra N., Goessl C., Kang J., Burgents J., Wu W., Kohlmann A., Adelman C.A, de Bono J.
JournalANNALS OF ONCOLOGY
Volume30
Pagination881+
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN0923-7534